Fifth, with the advent of targeted therapy and immunotherapy, conversion therapy for HCC with ipsilateral PVTT in the experimental group excluded TKIs and anti-PD-1 antibodies. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.